{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["8(7)"],"submitter":["Hentrich M"],"pubmed_abstract":["Results of a prospective study of stage-adapted treatment of human immunodeficiency virus (HIV)-associated Hodgkin lymphoma (HIV-HL) showed a 2-year overall survival (OS) of 90.7% with no significant difference between early favorable (EF), early unfavorable (EU), and advanced HL. Patients with EF HIV-HL received two to four cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) + 30 Gy involved field (IF) radiation, those with EU HIV-HL received four cycles of ABVD or BEACOPP (bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone) baseline + 30 Gy IF, and six to eight cycles of BEACOPP baseline were administered in advanced disease. The objective of the present analysis is to determine long-term outcomes of HIV-HL. Of 108 patients, 2"],"journal":["HemaSphere"],"pagination":["e68"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11221608"],"repository":["biostudies-literature"],"pubmed_title":["Stage-adapted treatment of HIV-associated Hodgkin lymphoma: Long-term results of a prospective, multicenter study."],"pmcid":["PMC11221608"],"pubmed_authors":["Wyen C","Muller M","Pferschy A","German HIV‐Related Lymphoma Study Group","Hentrich M","Schurmann D","Jurinovic V","Rockstroh JK","Hoffmann C","Siehl J"],"additional_accession":[]},"is_claimable":false,"name":"Stage-adapted treatment of HIV-associated Hodgkin lymphoma: Long-term results of a prospective, multicenter study.","description":"Results of a prospective study of stage-adapted treatment of human immunodeficiency virus (HIV)-associated Hodgkin lymphoma (HIV-HL) showed a 2-year overall survival (OS) of 90.7% with no significant difference between early favorable (EF), early unfavorable (EU), and advanced HL. Patients with EF HIV-HL received two to four cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) + 30 Gy involved field (IF) radiation, those with EU HIV-HL received four cycles of ABVD or BEACOPP (bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone) baseline + 30 Gy IF, and six to eight cycles of BEACOPP baseline were administered in advanced disease. The objective of the present analysis is to determine long-term outcomes of HIV-HL. Of 108 patients, 2","dates":{"release":"2024-01-01T00:00:00Z","publication":"2024 Jul","modification":"2026-05-29T11:44:47.984Z","creation":"2025-04-04T12:54:55.563Z"},"accession":"S-EPMC11221608","cross_references":{"pubmed":["38962576"],"doi":["10.1002/hem3.68"]}}